Breast Cancer PSMA PET
Recruiting
Early Phase 1
Interventional Study
Triple Negative Breast Cancer
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 90
- Sex
- Female
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Diagnostic
- Participants needed
- 30 (estimated)
- Sponsor
- Ahmad Shariftabrizi · Other
Who this trial is looking for
This trial is looking for women who are 18 years or older and have advanced breast cancer that has spread to other parts of the body. They also need to have specific results from a scan showing active cancer. However, they can't join if they have other active cancers, are pregnant or breastfeeding, or have health issues that would make scanning unsafe.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinic…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Female \>= 18 years of age
* Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.
* Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
Exclusion Criteria:
* Patients with know…
Contacts